Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 27, 1773-1778, October 1, 1967]
© 1967 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henderson, J. F.
Right arrow Articles by Paterson, A. R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henderson, J. F.
Right arrow Articles by Paterson, A. R. P.

Decreased Feedback Inhibition in a 6-(Methylmercapto)purine Ribonucleoside-resistant Tumor1

J. Frank Henderson, Ian C. Caldwell and A. R. P. Paterson

University of Alberta Cancer Research Unit (McEachern Laboratory) and Department of Biochemistry, Edmonton, Alberta, Canada

Some biochemical effects of 6-(methylmercapto)purine ribonucleoside (Me6MPR) have been compared in cells of the Ehrlich ascites carcinoma and of a Me6MPR-resistant subline. The sole metabolite of Me6MPR in both cell types was Me6MPR-5'-phosphate, and both formed the nucleotide at the same rate. This metabolite persisted for longer periods in the sensitive cells than in the resistant cells.

Me6MPR and guanine were less effective as feedback inhibitors of purine biosynthesis de novo in drug-resistant cells than in cells of the sensitive parent tumor, whereas adenine was equally effective in either. The phosphoribosylpyrophosphate amidotransferase activity of resistant cells was inhibited less than that of sensitive tumor cells. These results are consistent with the conclusion that the Me6MPR-resistant cells possess an altered amidotransferase which binds Me6MPR-5'-phosphate less well, or for which such binding has less inhibitory effect than for the enzyme in sensitive cells.

1 This work was supported by the Medical Research Council and the National Cancer Institute of Canada.

Received 2/ 6/67. Accepted 5/23/67.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1967 by the American Association for Cancer Research.